Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Statement

2 Nov 2017 07:00

RNS Number : 3058V
Elektron Technology PLC
02 November 2017
 

Elektron Technology plc

("Elektron", the "Group" or the "Company")

 

Trading Update

 

Elektron Technology plc (AIM: EKT), the global technology group, is pleased to provide an update on trading for the third quarter ended 31 October 2017.

Sales

Group trading was strong in Q3 with sales increasing 34% compared to the same period last year to £8.6m (2017: £6.4m). Year to date sales have increased by 15% to £22.9m (2017: £19.9m).

Bulgin achieved record quarterly sales of £7.8m in Q3, 37% higher than the same period last year (2017: £5.7m) following successful manufacturing scale-up to convert the unprecedented order demand in H1 into sales. The board expects that Bulgin sales will revert to more normal levels through Q4.

 

Sales £m

Unaudited

Unaudited

Q3 2018

Q3 2017

YTD 2018

YTD 2017

Bulgin

7.8

5.7

20.3

17.4

IMC (Queensgate and Elektron Eye Technology)

0.7

0.7

2.3

2.3

Checkit

0.1

0.3

0.2

 

Total

 

8.6

 

6.4

 

22.9

 

19.9

 

Orders

Group order intake remains well ahead of prior year, with all business segments demonstrating growth.

Bulgin and IMC orders are both 20% above prior year levels year to date.

Checkit has continued to build recurring revenue streams and total contracted annual recurring revenue (including forthcoming contracted installations) now stands at £0.7m, compared with £0.3m at the same time last year (+133%).

Cash

Group net cash was approximately £3.0m at 31 October 2017 (31 July 2017: £2.0m; 31 January 2017: £1.0m) following the initial proceeds from the Sheen Instruments disposal of £1.1m in October. The net cash position has also been impacted by investment in working capital of approximately £0.4m as a result of the strong trading performance in this quarter.

John Wilson, Chief Executive Officer of Elektron, said:

"Q3 trading has been strong. The Board now expects full year performance to be ahead of its previous expectations."

Enquiries:

 

Elektron Technology plc 

www.elektron-technology.com

 

+44 (0) 1223 371 000

John Wilson - Chief Executive Officer

 

Andy Weatherstone - Chief Financial Officer & Company Secretary

 

 

 

finnCap (Nominated Adviser & Broker)

+44 (0)20 7220 0500

Ed Frisby / Scott Mathieson - Corporate Finance

 

Abigail Wayne - Corporate Broking

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notes to Editors

Elektron conceives designs and markets innovative engineered products and services for businesses that connect, monitor and control. We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

 

- Demand for ubiquitous power and data: Bulgin

- New waves of "aware" business applications: Checkit

- The effect of ageing on sight: Elektron Eye Technology

- Growth in high precision manufacture: Queensgate

 

Cautionary statement

This financial information has been prepared only for the shareholders of Elektron as a whole and its sole purpose and use is to assist shareholders to exercise their governance rights. Elektron and its Directors and employees are not responsible for any other purpose or use or to any other person in relation to this report.

The report contains indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. Key risks and their mitigation have not changed materially in the period from those disclosed on pages 12 to 14 of the annual financial statements for the year ended 31 January 2017.

These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBUBDBCSGBGRB
Date   Source Headline
8th Apr 20269:54 amRNSForm 8.5 (EPT/RI)
7th Apr 202611:44 amRNSForm 8.3 - Checkit plc
7th Apr 202610:30 amRNSForm 8.5 (EPT/RI)
1st Apr 202610:37 amRNSForm 8.5 (EPT/RI)
1st Apr 20269:38 amRNSForm 8.3 - Checkit PLC
1st Apr 20267:47 amRNSForm 8 (OPD) - Checkit plc
31st Mar 20262:50 pmEQSForm 8.3 - Checkit PLC
31st Mar 202611:29 amRNSForm 8.3 - Checkit plc
31st Mar 202611:12 amRNSHolding(s) in Company
31st Mar 202610:51 amRNSForm 8.5 (EPT/RI)
30th Mar 20261:58 pmRNSForm 8.3 - Checkit plc
30th Mar 202610:14 amRNSForm 8.5 (EPT/RI)
27th Mar 20263:39 pmRNSForm 8.3 Check it
27th Mar 20262:43 pmRNSForm 8.3 - Checkit PLC
27th Mar 202611:44 amRNSForm 8.3 - Checkit plc
27th Mar 202611:36 amEQSForm 8.3 - Checkit PLC
27th Mar 202610:40 amRNSForm 8.5 (EPT/RI)
27th Mar 202610:32 amRNSCheckit Plc - Form 8.3
26th Mar 202610:26 amRNSForm 8.3 - Checkit PLC
26th Mar 20267:45 amRNSDisclosure Table
26th Mar 20267:00 amRNSCommencement of Formal Sale Process
19th Feb 20267:00 amRNSFY26 Trading Update
21st Jan 202611:34 amRNSHolding(s) in Company
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
28th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20257:00 amRNSDirector/PDMR Shareholding
4th Nov 20257:00 amRNSDirector/PDMR Shareholding
30th Oct 20251:00 pmRNSDirector/PDMR Shareholding
28th Oct 20257:00 amRNSDirector/PDMR Shareholding
13th Oct 20252:52 pmRNSGrant of options and PDMR dealing
25th Sep 20257:00 amRNSDirector/PDMR Shareholding
26th Aug 20257:00 amRNSInterim Results
19th Jun 20252:36 pmRNSGrant of Options
5th Jun 20253:11 pmRNSResult of AGM
29th May 20257:00 amRNSPosting of Annual Report and Notice of AGM
22nd May 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSFinal Results
17th Apr 20257:00 amRNSNotice of Results and Investor Presentation
8th Apr 20257:00 amRNSStrategic update
20th Mar 202512:31 pmRNSForm 8.5 (EPT/RI) - Amendment
20th Mar 202510:21 amRNSForm 8.5 (EPT/RI)
19th Mar 202512:02 pmRNSResult of General Meeting
18th Mar 20259:43 amRNSForm 8.5 (EPT/RI)
18th Mar 20259:23 amRNSForm 8.5 (EPT/NON-RI)
17th Mar 202512:01 pmRNSForm 8.5 (EPT/RI)
17th Mar 20258:56 amRNSForm 8.5 (EPT/NON-RI)
14th Mar 202511:57 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.